ACET - Adicet Bio, Inc. Stock Price, Fair Value and News

2.01USD+0.06 (+3.08%)Delayed as of 22 Apr 2024, 12:58 pm ET

Market Summary

USD2.01+0.06

Delayedas of 22 Apr 2024, 12:58 pm

3.08%

ACET Stock Price

View Fullscreen

ACET RSI Chart

ACET Valuation

Market Cap

160.2M

Price/Earnings (Trailing)

-1.12

Price/Sales (Trailing)

2.44

EV/EBITDA

Price/Free Cashflow

-1.63

ACET Price/Sales (Trailing)

ACET Profitability

EBT Margin

-208.72%

Return on Equity

-83.83%

Return on Assets

-68.82%

Free Cashflow Yield

-61.29%

ACET Fundamentals

ACET Revenue

Revenue (TTM)

68.3M

ACET Earnings

Earnings (TTM)

-142.7M

Earnings Growth (Yr)

1.29%

Earnings Growth (Qtr)

40.89%

Breaking Down ACET Revenue

52 Week Range

1.247.50

(Low)(High)

Last 7 days

-9.7%

Last 30 days

-8.9%

Last 90 days

-20.1%

Trailing 12 Months

-67.8%

How does ACET drawdown profile look like?

ACET Financial Health

Current Ratio

8.41

ACET Investor Care

Shares Dilution (1Y)

91.26%

Diluted EPS (TTM)

-3.31

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	38.7M	33.9M	73.8M	68.3M
2021	0	20.7M	16.7M	19.1M
2020	5.2M	9.4M	13.7M	17.9M
2019	0	0	0	995.0K
2018	0	0	0	8.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Adicet Bio, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 25, 2024	gordon carl l	bought	7,500,000	2.4	3,125,000	-
Jan 25, 2024	orbimed advisors llc	bought	7,500,000	2.4	3,125,000	-
Jan 24, 2024	aftab blake	acquired	-	-	19,700	chief scientific officer
Jan 24, 2024	harvey brian nicholas	acquired	-	-	26,300	chief financial officer
Jan 24, 2024	aftab blake	sold (taxes)	-8,556	2.4	-3,565	chief scientific officer
Jan 24, 2024	galimi francesco	sold (taxes)	-11,896	2.4	-4,957	svp & chief medical officer
Jan 24, 2024	harvey brian nicholas	sold (taxes)	-10,368	2.4	-4,320	chief financial officer
Jan 24, 2024	schor chen	sold (taxes)	-36,696	2.4	-15,290	president & ceo
Jan 24, 2024	healey don	acquired	-	-	19,700	chief technology officer
Jan 24, 2024	galimi francesco	acquired	-	-	26,300	svp & chief medical officer

Which funds bought or sold ACET recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	THOMPSON INVESTMENT MANAGEMENT, INC.	unchanged	-	37.00	188	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	69.53	171,680	326,634	0.01%
Apr 05, 2024	GAMMA Investing LLC	unchanged	-	-2,451	8,998	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	reduced	-88.00	-1,600	318	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.76	893,622	3,184,790	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	reduced	-3.84	26,626	108,156	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.41	7,769	28,548	-%
Feb 16, 2024	GSA CAPITAL PARTNERS LLP	reduced	-85.46	-156,000	39,000	-%
Feb 15, 2024	BARCLAYS PLC	added	664	72,000	79,000	-%

Are Funds Buying or Selling ACET?

Are funds buying ACET calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ACET

No. of Funds

Unveiling Adicet Bio, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 21, 2024	orbimed advisors llc	11.9%	9,772,598	SC 13D/A
Feb 27, 2024	millennium management llc	5.2%	3,946,142	SC 13G
Feb 14, 2024	ecor1 capital, llc	0%	0	SC 13G/A
Feb 14, 2024	rtw investments, lp	9.6%	4,134,631	SC 13G/A
Feb 14, 2024	tang capital partners lp	7.8%	5,900,000	SC 13G/A
Feb 12, 2024	morgan stanley	6.4%	2,777,725	SC 13G
Feb 07, 2024	carlyle group inc.	4.1%	3,060,292	SC 13D/A
Feb 07, 2024	blackrock inc.	3.0%	2,111,898	SC 13G/A
Feb 05, 2024	ra capital management, l.p.	9.99%	7,696,949	SC 13G
Feb 02, 2024	cowen financial products llc	6.29%	2,715,278	SC 13G/A

Recent SEC filings of Adicet Bio, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 12, 2024	PRE 14A	PRE 14A
Mar 22, 2024	424B5	Prospectus Filed
Mar 22, 2024	8-K	Current Report
Mar 21, 2024	SC 13D/A	13D - Major Acquisition
Mar 19, 2024	10-K	Annual Report
Mar 19, 2024	8-K	Current Report
Mar 19, 2024	S-8	Employee Benefits Plan
Mar 19, 2024	S-8 POS	Employee Benefits Plan
Feb 27, 2024	SC 13G	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Adicet Bio, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-1.66%	-28.18%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.46%	-28.84%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	4.57%	-8.46%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-10.11%	-29.11%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.66	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-13.81%	-4.67%	-13.45	11.89	440.80%	-27.84%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.22	3.82	40.45%	71.62%
ARWR	2.8B	240.7M	-20.67%	-25.33%	-9.32	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-17.39%	-51.52%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-0.38%	387.14%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-10.29%	-2.81%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	59.81%	33.59%	-0.22	2.14	-13.45%	66.37%

Adicet Bio, Inc. News

Latest updates

Adicet Bio, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Revenue	-	-	-	43,360,000	-	24,990,000	5,468,000	3,429,000	4,814,000	5,410,000	3,028,000	7,465,000	2,000,000	-	-
Operating Expenses	0%	31,565,000	31,565,000	22,985,000	22,707,000	20,284,000	21,010,000	17,139,000	15,641,000	14,759,000	16,683,000	16,095,000	9,557,000	1,245,500	-10,200,000
S&GA Expenses	3.9%	6,806,500	6,550,000	6,415,000	6,529,000	6,801,000	6,352,000	5,213,000	5,025,000	5,076,000	7,741,000	7,419,000	2,524,000	2,006,500	1,799,000
R&D Expenses	-1.0%	24,758,500	25,015,000	16,570,000	16,178,000	13,483,000	14,658,000	11,926,000	10,616,000	9,683,000	8,942,000	8,676,000	7,033,000	-761,000	-11,999,000
EBITDA Margin	-103.6%	-2.00	-0.98	-0.73	-1.36	-0.89	-3.16	-3.22	-2.64	-	-	-	-	-	-
Interest Expenses	-98.1%	500	26,000	18,000	18,000	18,000	25,000	50,000	51,000	-	50,000	34,000	-	-	-
Income Taxes	-	-	-	-	-	-	-11,000	11,000	-77,000	-139,000	3,000	-	-2,679,000	3,000	-
Earnings Before Taxes	1.3%	-29,489,000	-29,874,500	-21,996,000	-22,538,000	4,618,000	-15,824,000	-14,002,000	-10,931,000	-9,097,000	-14,776,000	-8,455,000	-7,165,000	4,740,500	21,969,000
EBT Margin	-104.4%	-2.09	-1.02	-0.76	-1.41	-0.93	-3.25	-3.32	-2.71	-	-	-	-	-	-
Net Income	1.3%	-29,489,000	-29,874,500	-21,996,000	-22,538,000	4,618,000	-15,813,000	-14,013,000	-10,854,000	-8,958,000	-14,779,000	-8,455,000	-4,486,000	-28,890,000	-5,757,000
Net Income Margin	-3189.5%	-2.09	0.07	-0.75	-1.41	-0.93	-3.24	-3.31	-2.70	-	-	-	-	-	-
Free Cashflow	6.7%	-23,622,000	-25,327,000	-20,139,000	-17,554,000	1,473,000	-16,522,000	-16,862,000	-14,910,000	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-11.1%	207	233	278	305	331	354	330	340	339	257	269	282	154	150	74.00	78.00	82.00	122	137	145	110
Current Assets	-12.7%	162	186	209	235	261	286	264	282	282	199	216	229	100	117	74.00	78.00	64.00	121	136	145	110
Cash Equivalents	-12.8%	160	183	205	232	258	283	261	278	278	192	209	222	89.00	85.00	18.00	7.00	15.00	23.00	21.00	7.00	9.00
Net PPE	-5.3%	27.00	28.00	30.00	30.00	29.00	27.00	23.00	18.00	15.00	11.00	11.00	3.00	3.00	2.00	0.00	0.00	2.00	0.00	0.00	0.00	0.00
Goodwill	-	-	-	19.00	19.00	19.00	19.00	19.00	19.00	19.00	19.00	19.00	20.00	20.00	21.00	-	-	-	-	-	-	-
Liabilities	-3.8%	37.00	39.00	39.00	39.00	38.00	37.00	37.00	29.00	36.00	40.00	40.00	46.00	44.00	33.00	4.00	3.00	28.00	12.00	10.00	5.00	6.00
Current Liabilities	-2.4%	19.00	20.00	19.00	18.00	20.00	17.00	16.00	10.00	16.00	20.00	21.00	25.00	22.00	30.00	4.00	3.00	15.00	12.00	10.00	5.00	6.00
Shareholder's Equity	-12.6%	170	195	239	266	292	318	293	311	303	217	228	236	110	117	71.00	76.00	82.00	110	127	140	104
Retained Earnings	-8.4%	-380	-351	-301	-268	-238	-208	-186	-163	-168	-152	-138	-127	-106	-97.37	-166	-161	-69.65	-125	-100	-82.46	-71.39
Additional Paid-In Capital	0.9%	551	546	540	535	530	526	480	475	471	370	367	364	216	214	238	237	9.00	235	228	223	176
Shares Outstanding	0.4%	43.00	43.00	43.00	43.00	43.00	41.00	40.00	40.00	40.00	32.00	29.00	26.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	77.00	-	-	-	428	-	-	-	226	-	-	-	40.00	-	-	-	278	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-10.6%	-23,486	-21,238	-24,899	-24,094	-18,837	-15,328	-14,705	4,105	-13,444	-9,684	-12,778	-15,146	-13,345	-7,849	-12,006	-8,352	-7,259	5,601	-14,175	-12,049	9,625
Share Based Compensation	-11.7%	4,911	5,560	5,023	4,765	4,250	4,191	4,335	4,350	4,280	2,529	2,659	3,043	1,647	3,116	52.00	299	397	14.00	14.00	663	774
Cashflow From Investing	85.0%	-136	-906	-1,507	-1,915	-6,490	-4,811	-2,849	-2,632	-3,078	-7,178	-382	7,842	12,448	74,646	23,678	4,445	-5,014	-33,265	24,976	-34,628	76,568
Cashflow From Financing	228.8%	76.00	-59.00	226	-7.00	304	42,176	163	-1,134	97,463	362	-27.00	144,887	267	144	-150	42.00	-123	26,702	3,550	46,816	-78,892

ACET Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue related party	$ 0	$ 24,990
Operating expenses:
Research and development	106,043	71,246
General and administrative	26,533	26,295
Goodwill impairment	19,462	0
Total operating expenses	152,038	97,541
Loss from operations	(152,038)	(72,551)
Interest income	9,978	3,760
Interest expense	(25)	(80)
Other expense, net	(573)	(919)
Loss before income tax provision	(142,658)	(69,790)
Income tax provision	0	0
Net loss	$ (142,658)	$ (69,790)
Net loss per share attributable to common stockholders, basic	$ (3.31)	$ (1.7)
Net loss per share attributable to common stockholders, diluted	$ (3.31)	$ (1.7)
Weighted-average common shares used in computing net income (loss) per share attributable to common stockholders, basic	43,042,405	41,080,286
Weighted-average common shares used in computing net income (loss) per share attributable to common stockholders, diluted	43,042,405	41,080,286

ACET Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 159,711	$ 257,656
Prepaid expenses and other current assets	2,561	3,382
Total current assets	162,272	261,038
Property and equipment, net	26,777	28,710
Operating lease right-of-use asset	17,424	20,269
Goodwill	0	19,462
Other non-current assets	822	1,211
Total assets	207,295	330,690
Current liabilities:
Accounts payable	2,625	4,404
Accrued and other current liabilities	13,441	12,811
Operating lease liability	3,221	2,492
Total current liabilities	19,287	19,707
Operating lease liability, net of current portion	17,703	18,531
Other non-current liabilities	130	114
Total liabilities	37,120	38,352
Commitments and contingencies (Note 9)
Stockholders’ equity (deficit):
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; none issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	0	0
Common stock, $0.0001 par value, 150,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; 43,270,386 and 42,954,820 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	4	4
Additional paid-in capital	550,943	530,448
Accumulated deficit	(380,772)	(238,114)
Total stockholders' equity	170,175	292,338
Total liabilities and stockholders' equity	$ 207,295	$ 330,690

About Adicet Bio, Inc.

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.

CEO	Mr. Chen Schor BA, CPA, CPA, M.B.A., MBA
WEBSITE	adicetbio.com
INDUSTRY	Biotechnology
EMPLOYEES	132

Adicet Bio, Inc. Frequently Asked Questions

What is the ticker symbol for Adicet Bio, Inc.? What does ACET stand for in stocks?

ACET is the stock ticker symbol of Adicet Bio, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Adicet Bio, Inc. (ACET)?

As of Fri Apr 19 2024, market cap of Adicet Bio, Inc. is 160.2 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACET stock?

You can check ACET's fair value in chart for subscribers.

What is the fair value of ACET stock?

You can check ACET's fair value in chart for subscribers. The fair value of Adicet Bio, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Adicet Bio, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ACET so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Adicet Bio, Inc. a good stock to buy?

The fair value guage provides a quick view whether ACET is over valued or under valued. Whether Adicet Bio, Inc. is cheap or expensive depends on the assumptions which impact Adicet Bio, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACET.

What is Adicet Bio, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, ACET's PE ratio (Price to Earnings) is -1.12 and Price to Sales (PS) ratio is 2.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACET PE ratio will change depending on the future growth rate expectations of investors.